Cannabis-like synthetic compound delivers pain relief without addictive high, study finds
U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...
Investing Snacks1d
Vertex’s Journavx Poised for Big Outpatient Market Win
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
2minutemedicine.com1d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...
BioSpace2d
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
The secret soldiers knew: How to make your brain switch off pain like a light, without using painkillers
Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...
AFP8d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia.
RBC says Journavx review documents hint at focus in future chronic pain data
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
BioSpace10d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
WRIC10d
FDA approves first opioid-free painkiller in over two decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...
Facebook | The Stute13d
FDA approves first-of-its-kind non-opioid pain medication
On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...